Since JAK2–STAT3/NF-κB inflammatory signaling contributes to the activation of CAFs, we next explored whether blocking this inflammatory signaling could inhibit EMT of CRC cells by using STAT3 and NF-κB inhibitors. The gene discussed is JAK2; the disease is colorectal carcinoma.